© 2023 BioMarin. All rights reserved.

BioMarin to Participate in the Virtual BofA Securities 2020 Napa Biopharma Conference
Jun 23, 2020

SAN RAFAEL, Calif., June 23, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Henry Fuchs, M.D., President, Worldwide Research & Development and Brian Mueller, Acting Chief Financial Officer, will participate in the BofA Securities 2020 Napa Biopharma Conference on June 24, 2020 at 11:30am ET.  An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.  

For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.




Traci McCarty

Debra Charlesworth

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558

(415) 455-7451


SOURCE BioMarin Pharmaceutical Inc.